Zilico Limited Company
Zilico is focused on developing next generation cancer diagnostics to provide real-time diagnosis for cervical cancer. Zilico's flagship product, ZedScan is a diagnostic for cervical cancer. It is in routine use across several hospitals in the NHS.
Industry:
Pelvic & Uterine Healthcare
Headquarters:
Manchester, Manchester, United Kingdom
Founded Date:
06-02-2006
Employees Number:
11-50
Investors Number:
8
Total Funding:
$23,546,581
Estimated Revenue:
$1M to $10M
Last Funding Date:
2018-02-04
Last Funding Type:
Corporate Round
Register and Claim Ownership